Bronchogen
A Khavinson tetrapeptide from bronchial tissue — proposed to support respiratory epithelium function in chronic obstructive airway disease; evidence is preliminary and Russian-language.
One of the Khavinson short-chain bioregulators (Ala-Glu-Asp-Leu), derived from bronchial mucosal extract and proposed to support epithelial regeneration and ciliary function in aging lung tissue and in chronic obstructive pulmonary disease models.
Mechanism of action
Proposed to act on bronchial epithelial cells via promoter binding to upregulate expression of genes supporting ciliary function and epithelial repair. Khavinson-group animal studies report reduced inflammation and improved mucociliary clearance in experimental COPD models.
Primary uses
- Investigational adjunct in chronic obstructive pulmonary disease (Russian literature)
- Research into respiratory aging
Typical dosing
Russian supplement protocols typically use 10 mg oral capsules once daily for 10–20 days.
Regulatory status
Not FDA-approved. Marketed in Russia as a bioregulator supplement.
References
- [pubmed] Khavinson VK, Kuznik BI, Ryzhak GA. "Peptide bioregulators: a new class of geroprotectors. Message 1. Results of experimental studies." Adv Gerontol, 2012;25:696-708.
- [review] Khavinson VK, Malinin VV. "Gerontological aspects of genome peptide regulation." Karger AG, Basel, 2005.
Related peptides
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.